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tX&dives. The parpose of tbis study was to evaluate the effects 
of mibefradil (Ro 40.5%7) on tbe frequency and dnratioa of 
episodes of asymptomatic ischemia in patients with stable angina 
pectork and to determine tbe most e&ient single therapeutic 
dose of tbii drug. 
Backgnnmd. Mibefkadil is a novel calcium channel antagonist 
that shows a high bioavailability, iadores DO rellex tachycardi 
and has no uegative inotropic e&k 
&#a&. In a multicenter, double-bliad, @&o-controlled, 
pmallel-des~p trial+ 126 patients with clthronie stable angina 
peetoris were studied. After 1 welt of a placebo rtm-in pet&x& 
patients wxe rtmdomlzed to receive 25, 50, MO, 1% mg of 
&efradil or placebo for 2 weeks. Ambulatory d8-h efortrorardi 
graphic (ECG) monitoring was performed at the end of both tbe 
placebo nm-in period and the a&e treatment period. 
I&s&s. Compared with placebo, mihef&il was associated 
The phenomenon of silent transient ischemia recorded dur::g 
ambulatory electrocardiographic (ECG) mor:itor brig has at, 
tracted a great deal of clinical and investigative interest (I-4). 
Kecent reports (S-S) of 48-h ST segment monitoring in 
patients with stable angina pectoris receiving standard medical 
therapy suggest that between 40% and 47% of these patients 
have ischemic episodes, the majority without angina, during 
daily activities. Transient ice’ qia occurs predominzntiy in 
patients with psitive exercik lest results at low work loads 
(6.9). A varies) of anti-ischei ‘: drugs have beer: studied as 
treatment for episodes of ambulatory asymptoaltic ischemia, 
but those controlled, double-blind trials included only a small 
number of patients, and there was a lack of definitive compar- 
isons (10). 
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with signilicaotly less iscbemia as manifested during ambuls*ory 
ECG monitoring. In tbe 150- and lOO-mg groaps, respectively, the 
d~resultedina7~and~redortionintho6reqwoeyol 
episodes of ST’ segment depressioo sad a 78% and 58% reductioa 
in the total daratioa of !5T segment depresGi. H!gldy significant 
liaear dose-response relations were present across all treatment 
gronps for isshemic episodes aad ischemia duration (p < O.%l). 
Ehrocardiograpltic abmmaalities related to treatmeat wenz 
IIrstdepe atrioveathcular block sinus bradycardia aad short 
Wenckebd episodas, observed duriag sleep 08 Halter moaitor- 
Ing.AREcGevelttsweredosfl-dated. 
I is a nea, safe, nell toleratrd aad veq 
anti-ihemic calcium chaaael antag+ 
nist. 
(J Am Call Gmlid 1996;2?317-221 
Mibefradil (Ro 4O-5%7) is a novel calcium channel blocker 
that combines the properties of high bioavailability, a once- 
daily regimen without galenic manipulation, the absence of 
reflex tacbycardia or edema. or both, and a lack of negative 
inotropic effects (11-20). The purpose of this study was to 
determine the effects of mibefradil on the frequency and 
duration of episodes of asymptomatic ischemia in patients with 
stahle exertional angina pectoris, as well as to determine the 
most efficient single therapeutic dose of this agent. 
Metbds 
Sttldy design. A multicenter. double-blind. placebo- 
controlled, paralleldesign study was performed in 11 centers 
in 8 cocnties (Austria, Finland, Fran=, Germany, Israel, The 
Netherk&s. Sweden and Switzeriand) after approval by 
the local ethics committees. It was conducted according to the 
Helskini Declarati$ as amended in Tokyo and Venice. 
Patients were eligible for inclusion if they satisfied all of the 
following criteria. 1) They had coronary artery disease docu- 
mented by at least one of the foliowing: cororuary angiogram 
indicating at least one or more major coronary arteries or 
major branches with W)rh reduction in lumen diameter; 
documented myocardial infarction; reversible perfusiin defect 
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Figure 1. Study design. 
during stress-redistribution thallium-2Fl scintigraphy; or 
rl.O-mm horizontal or a downsloping ST segment depression 
on an exercise test; 2) they had a stable pattern of angina 
pectoris for ~3 months before screening; 3) they had effort- 
induced angina pectoris on a bicycle exercise test; and 4) they 
were able to exercise ~3 min at a work load of 25 W. The 
results of the exercise tests have been reported elsewhere (21). 
Patients were excluded if they had any of the following: 1) 
myocardial infarction or cardiac surgery within 3 months, or 
coronary angioplasty within 6 months, of the screening visit; 2) 
congestive heart failure; 3) bradycardia, atrioventricular (AV) 
block or any clinical significant arrhythmia; 4) uncontrolled 
hypertension (blood pressure >180/105 mm Hg) or hypoten- 
sion (blood pressure <loo/60 mm Hg): 5) major systemic 
die; 6) a history of alcohol or drug abuse; or 7) childbear- 
ing potential. 
Study prutaeal (Fig. 1). During a 2-week washout period, 
previously ingested anti-angina] medications (beta-adrenergic 
blocking agents, long-acting nitrates and calcium antagonists) 
were gradually discontinued, and only short-acting sublingual 
nitrates for aborting angina1 attacks were allowed during the 
study period. Patients entered a l-week placebo run-in period 
in which three exercise tests were performed on 3 different 
days. If patients were randomized to one of the five study 
groups (placebo or 25,50,100, or 150 mg of the study drug) for 
2 weeks of active treatment, exercise tests were performed at 
the end of each week at the same time of day. Patients were 
asked to complete a diary every week throughout the study to 
assess the number of angina1 episodes and total nitroglycerin 
consumption. 
Ambulatory EC@ monitoring. Ambulatory ECG record- 
ings were performed with the use of AC!&8500 cassette 
recorders. Electrodes were applied to record a modified lead 
Vs and a modified lead aVF. After the leads were connected to 
the patient but before the ambulatory recording session was 
initiated, a cable from the recorder was inserted into a 
standard ECG machine. Recordings were made in different 
positions to ensure that artificial ST segment deviation did not 
occur. The recordings were analyzed by the Holter ECG Car 
Laboratory (Lausanne, Switzerland). The technician and the 
physician were unaware of medication assignment or treat- 
ment regimen. An ischemic episode was de&ted as transient 
isehemic ST segment depression ~1.0 mm and Ibting 21 min. 
The variables evaluated included the number of episodes of ST 
JACC Vol. 27, No. 2 
February 19’%317-22 
segment depression and the total duration (in minutes) of 
&hernia. Ambulatory 48-h ECG monitoring was performed at 
the end of both the placebo run-in period and the active 
treatment period. Episodes of ischemia identified by ambula- 
tory ECG were correlated with symptoms identified in the 
patient’s diary to determine whether the ischemic events were 
silent or associated with angina. 
Statistical analysis. Statistical analysis was performed on 
the differences between the results of the ambulatory ECG 
recnrded at baseline and at week 2. To show the dose-response 
relation, a linear trend test was performed by applying the 
appropriate linear hypothesis in the analysis of variance with 
the treatment effect. To show the individual dose effect, a 
pairwise comparison of each dose group with placebo was 
made by using the appropriate contrast of the linear model. 
The Jonckheere-Terpstra te%t (22) was used to test the previ- 
ously mentioned hypotheses. A close test (23) was applied to 
ensure that the normal significance level was kept at 5%. 
Results 
Patient cheracteristics. Of 245 patients with angina pecto- 
ris who were screened for eligibility to participate in the study, 
171 entered the placebo run-in period. During this period, 45 
patients either did not qualify for randomization or discontin- 
ued treatment for administrative reasons. A total of 126 were 
randomly assigned to the five treatment groups. Five patients 
were classified as protocol violators and three patients did not 
complete the active treatment period because of adverse 
events. All 126 patients had ambulatory baseline ECG record- 
ings and were eligible for analysis. Of these 126 patients, 45 
patients (37%) showed evidence on the first ambulatory ECG 
recording of having had at least one episode of silent ischemia. 
The average age of the study population was 59.3 -C 8.0 years; 
82% were men. 
Effect of q ibefrodil on beart rate and blood pressure. The 
administration of mibefradil was associated with a slight but 
highly significant dose-dependent decrease in heart rate and 
systolic and diastolic blood pressure (Table 1). 
E&t of mibefradil on episodes of ambulatory rscbemia 
Qable 2). Symptomatic episodes of ischemia detected on 
ambulatory ECG monitoring were excluded for the subsequent 
analyses. Mibefradil was associated with significantly less isch- 
emia as manifested during ambulatory ECG monitoring than 
was placebo (Fig. 2). In the 150- and lOO-mg groups, respec- 
tively, the drug resulted in a 73% and 63% reduction in the 
frequency of episodes of ST segment depression and a 78% 
and 58% reduction in the total duration of ST segment 
depression. There was a significant linear dose trend (dose- 
response relation) toward a decrease in ischemic episodes and 
&hernia duration in the ambulatory ECG recordings (p c 
0.001). 
E&t of mibefradil on episodes of angina pec&s. Mibe- 
fradil was associated with signhlcantly fewer anginaI episodes 
than was placebo. In the 150- and lOO-mg groups, respectively, 
it resulted in a 51% and 50% reduction in the frequency of 
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Table I. Changes From Baseline in l~emodynamic Variables at Rest 
Mihefradil 
- 
PlaC&l 2s mg -50 mg loo mg IHI mg p Value 
(n = 27) (n = 2s) (n = 25) (R L B) (n _ 23) (hy linear trend Ifu) 
SBP (mm Hg) -1112 -3-15 -6: 10 -xi Ih -R c I? Il.MJS 
DBP (mm Hg) O?fi -227 -4 f b -5 ? 7 -7:x rlall 
HR (kats/min) 129 -I?H --I _f9 -5 + 10 -6 z 10 O.MJ I 
Values are expresed as mean value 2 SD. DBP = diastolic blood ptcswe: HR = hear! rate: SBP = ~w11ic hlwd 
anginal episodes/week and a 79% and 61% reduction in 
nitroglycerin consumptiotieek. A dose-dependent decrease 
in the number of anginal episodes and the rate of nitroglycerin 
constumptiomweek was observed across the active treatment 
groups. However, although no improvement was observed in 
the 25mg dose group of mibefradil, all other groups did better 
than the placebo group (linear trend test, p i 0.01). 
TolerabiPg and safety. Mibefradil was well tolerated. 
When all nontreatment-related and treatment-related adverse 
events were considered, no differences were observed between 
patients taking mibefradil and those receiving placebo (27% vs. 
30% for all adverse events combined and 18% vs. 22% for 
treatment-related adverse events alone). Aggravated angina 
was reported in 14% of the placebo group and in 2% of the 
mibefradil groups. The most frequently occurring adverse 
events observed in the patients treated with mtbefradil or 
placebo were, respectively, dizziness (7% vs. 3.7%). gastralgia 
(2% vs. O%), flushing (2% vs. 0%) and headaches (3.7% vs. 
3.0%). 
When ECG abnormalities related to treatment were con- 
sidered, the main events observed in the mibefradil groups 
were first-degree AV block (8%, maximal PQ interval 240 ms), 
sinus bradycardia (5%) and short Wenckebach episodes, ob- 
served during sleep on Holter ambulatory ECG monitoring 
(5%). All ECG events were dose related (Table 3). 
Discussion 
Our results indicate that mibefradil was effective in reduc- 
ing the frequency and duration of asymptomatic irhemic 
episodes in patients with stable exertional angina pectoric and 
asymptomatic iahemia. 
The significant linear trends observed throughout the tive 
treatment groups with regard to I) the number of events and 
duration of silent irhemis, and 2) the decrease in weekfy 
angina1 attacks and nitrogtycerin consumption clearly indicate 
that the increase in the dose of mibefradil from 0 (placebo) to 
150 mg/day, after 2 weeks of active treatment, is associated 
witn a signiftcant improvement in the clinical conditio;: of 
patilnts with chronic. stable excrtional angina pectoris. Treat- 
ment with the three higher dose levels of mibehadil was 
asssiated with a significant improvement in all the evaluated 
indexes of ischemia (3). However, the differences between the 
NO- and the 150-mg doses of mtmefradil were small and 
clinically nonsignihcant. suggesting that the lS@mg dose is at 
the plateau of the dose-rqxmse curve and may be the highest 
effective dose. 
cQntpprisou with other cakium cslanwf ml- Al- 
though &urn channel antagonists have been demonstrated 
to be elective for symptomatic iscbemia, studies evahutting 
their ethcacy in the suppression of asymptomatic ischemic 
episodes on continuous ECG recordirtgs have had mixed 
results. Bala Subramanian et al. (24) demonstrated a signifi- 
cant reduction in the number of asymptomatic episodes with 
verapamil. but not with short-acting nifedipine. Frishman et al. 
(25) performed a crossover study with diltiazem and nifedi- 
pine. Although both drugs had a similar effect on exercise 
tolerance, only diltiamm suppressed asymptomatic ischemic 
episodes. Deedwania et al. (26) compared the anti-ischemic 
efficacy of nifedipine and atenolol and found that both agents 
Sit kdxmk Episk (II = 10) \n = ii) ((I = 9, (,I = IL) (R = 7) & LineartreKlM) 
-- 
NO. 
Ekelii 53 2 4.7 27i-ll 5.5~65 5.1 f 5.1 10.9 f tah - 
fi%angefmmhasclii 15-+5.0 0.2223 -15+-4.1 -32 z 3x -11.0 I h.7 - 
Placebo- - -1.Y -4.1 -5.7' -9,fJt aa) 
Dtmtim (mid 
B5zdne 7.9 + 116 21 r22 %!rl(L\ 43552 llb~11~ - 
cbangehonlt?areline n-63 -3~6 -43tti -25 2 49 -Ylr% - 
Racebocormacd - -2-i -91' -xi -iT" <: aall 
*pc0.01.tp<0.02DataareexpescdzpmeanvahreMmeanMlue+SD. 
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strated a 67% reduction in the number of asymptomatic 
ischemic episodes with diitiazem. In their large scale piacebo- 
controlled study, Stone et al. (28) found that neither nifedipine 
nor diltiazem demonstrated a significant effect on the number 
of asymptomatic episodes of &hernia. In comparison, pro- 
pranoioi exhibited a profound effect, reducing both the num- 
ber and the duration of asymptomatic ischemic e&odes. 
The less potent anti-ischemic ei?ects reported with calcium 
channel antagonists in comparison with beta-blockers may be 
due in part to the less potent reduction by the former agents of 
indexes of myocardiai oxygen demand. In addition, many of 
the dihjjdropyridine calcium antagonists tested are short-acting 
preparations, causing significant peaks and troughs in serum 
levels and thereby exposing the patients to the risk of reflex 
tachycardia associated with a transient reduction of blood 
pressure. 
41 
2 1 1.5 
ea 
E 
9 
al 
‘I’,‘,‘,’ ‘,‘,‘,.,’ 0.2 0 ‘lL’1.1. 
,,,,, . . . . . ,l,,, 
1”91 
.I... 1111, .\\.. 
-2 -1 5 
-4 
-6 
-8 1 
1,1,, \\\I\ ,1,,  . . \ I,,  \\L. , 11, u S.\\\ 1,,,. .  , , \\\% ,,,, \ .
-3 2 
-8 
.lOJ\ 
placebo 25 50 100 150 
Mibefradil (mg) 
Figure 2. Bar graph showing changes in th; number and duration of 
silent isehemic events with mibefradil treatment. A significant linear 
dose-response relation is shown across all treatment groups for 
iachemic events and isehemia duration (p < 0.001). 
had a significant suppressive effect on asymptomatic &hernia, 
but the magnitude of the suppression by the beta-blocker was 
significantly larger than ;hat of the calcium channel antagonist. 
In a placebo-controlled study, Theroux et al. (27) demon- 
Table 3. Overvir* of Clinically Relevant Electrocardiographic Abnormalities Related to Trentment 
Mibefradil 
Placebo 25 mg so mg 100 mg 150 mg All Mibefradil 
(n = 27) (‘I = 25) (n = 25) (n = 26) (n = 23) Groups (n = 99) 
PQ inlcrval > MO ms 1(4%) 1(4%) 1(4%) 1(4%) 5 (22%) 8 (8%) 
Sinus bra&cardia L - 1(4%) 2 (8%) 2 (80) 5 (5%) 
Wenckebachcundu&n* - - 1(4%) -' 4(17%) 5 (5%) 
Patients with EKG 1(4%) 1(4%) 3 (12%) 3 (12%) 9 (39%) 16(16%) 
abnormalities 
‘As as.ses+xd by Holter ambulatory eleetrocardiographii (ECG) moniloring at night. Data are expressed as number 
(%) of patients. 
Anti-isehemic mechanisms of mibefradil. The profound 
effect of mibtfradii on reducing asymptomatic ischemic epi- 
sodes may be explained by the unique properties of this agent 
compared wirh those of other calcium antagonists. Preclinicai 
studies have suggested that mibefradii has combined pharma- 
codynamic and pharmacokinetic characteristics that are iack- 
ing in other calcium antagonists. The significant effect on silent 
&hernia was associated with a slight but significant dose- 
related decrease in heart rate and blood pressure; no reflex 
tachycardia was observed. The effects of mibefradii on heart 
rate are probably related to a direct effect on the sinus and AV 
nodes, probably through the inhibition of calcium ion influx 
(16-19). This effect could be mediated through the blockade of 
the L-type or T-type, 0: both, calcium channels that exist at the 
level of the sinus and AV nodes. A selective inhibition of the 
T-type channels by mibefradii was recently demonstrated (29). 
It was suggested (30) that the better anti-ischemic effect of 
slow release nifedipine on silent &hernia compared with that 
of the short-acting form may be related to its mode and 
duration of administration; the long-acting preparation is less 
likely to produce proischemic reflex tachycardia and therehy 
allows a greater anti-ischemic effect. Mibefradii has a duration 
of action of >24 h, which is longer than that of the first- 
generation calcium antagonists. It has a high bioavailabiiity 
and a long half-life, and the plasma concentrations achieved 
with chronic dosing are linearly correlated with dose. These 
properties ensure small interpatienr variability and high con- 
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sistency, in contrast to the conditions associated with verapamil 
a?d nifedipine in the regplar galenic formulation (i.e., not the 
slow release formulation). 
A reduction of coronary blood flow is another mechanism 
hypothesized to induce silent &hernia. Normal variation in the 
tone of the coronary arteries causes reductions of 10% to 25% 
in the outer diameter of the arteries (31,32). In an artery with 
intimal thickening, even a small increase in vasomotor tone can 
result in either subtotal or total occlusion of the lumen. Brown 
et al. (33) demonstrated a reduction of up to 33% in coronary 
artery lumen during handgrip exercise in patients with stable 
angina pectoris. Gage et al. (34) showed both a 71% reduction 
in coronary stenosis area with dynamic exercise and its pre- 
vention by pretreatment with nitroglycerin. Mibefradil induces 
a selective vasodilation in the coronary vascular bed. In two 
models mimicking the consequences of coronary atherosclero- 
sis (11,12), experiments with radioactive microspheres have 
shown that Mibefradil is a strong vasodilator in the subendo- 
cardium and therefore does not produce a steal phenomenon. 
These properties may explain its efficacy in reducing silent 
ischemia in patients with stable angina pectoris. 
Conclusions. Mibefradil is a potent novel calcium antago- 
nist with a dose-dependent high response rate for silent 
ischemic episodes. its excellent efficacy and safety profile, 
combined with its high bioavailability in a once-a-day regimen, 
and the absence of reflex tachycardia and edema make it a very 
promising new compound for treatment nf patients withangina 
pcctoris and silent ischemia. The combination of this unique 
compound with other anti-ischemic drugs (having different 
anti-ischemic mechanisms) might even enhance the anti- 
ischemic effect. Further clinical trialsare needed to asses the 
efficacy and safety of mibefradil in combination with other 
calcium antagonists and beta-blocking agents and in patients 
with impaired left ventricular function. 
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Principal Investigators and Participating Instihttions 
in the Mibefradil International Study Group 
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